EntryPoint Capital’s Catalyst Pharmaceutical CPRX Stock Holding History
Bought
Maintained
Sold
Other funds holding CPRX
GCL
HI
EntryPoint Capital's CPRX Position: Q2 2026 in Review
EntryPoint Capital sold out of Catalyst Pharmaceutical (CPRX) in Q2 2026, closing a stake of 19,539 shares — an estimated $484K sold.
EntryPoint Capital first reported a position in CPRX in Q4 2023 and held it in 6 quarters. The position peaked at $484K in Q1 2026. 396 funds tracked by Wall St. Rank hold CPRX as of Q2 2026.
- EntryPoint Capital reported no remaining Catalyst Pharmaceutical position as of Q2 2026 after selling out during the quarter.
- EntryPoint Capital sold 19,539 Catalyst Pharmaceutical shares in Q2 2026, an estimated $484K.
- EntryPoint Capital first reported a position in Catalyst Pharmaceutical in Q4 2023 and held it in 6 quarters.
- EntryPoint Capital's Catalyst Pharmaceutical position peaked at $484K in Q1 2026.
- 396 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q2 2026.
Based on EntryPoint Capital's 13F filing for Q2 2026, filed 13 Aug 2026.